Elan/Biogen Idec update Tysabri's US label
This article was originally published in Scrip
Executive Summary
Elan and Biogen Idec have updated the US label of their multiple sclerosis drug Tysabri (natalizumab) to re-emphasise that it carries a risk of inducing the rare, but potentially fatal, brain infection progressive multifocal leukoencephalopathy (PML).